Quinine‑Associated Tinnitus: A Complete Medical Guide

Overview

Quinine‑associated tinnitus is the perception of ringing, buzzing, or other phantom sounds in the ears that occurs as a side‑effect of quinine‑containing medicines. Quinine, an alkaloid originally derived from the bark of the cinchona tree, is most widely recognized for its historical use in treating malaria and, in lower doses, for relieving nocturnal muscle cramps. Although the drug is effective for these indications, it can affect the auditory system, leading to tinnitus that may be temporary or, in rare cases, permanent.

**Who it affects** – Anyone taking quinine can develop tinnitus, but the risk is higher in:

• Adults ≥ 50 years old (age‑related changes in cochlear blood flow)
• Patients with pre‑existing hearing loss or otologic disease
• Individuals taking higher than recommended doses or using quinine for off‑label purposes (e.g., chronic leg cramps)
• People with renal or hepatic impairment, which slows drug clearance

**Prevalence** – Large pharmacovigilance databases estimate that auditory side‑effects occur in 0.2 %–0.5 % of patients prescribed quinine for malaria prophylaxis, and up to 1 %–2 % in those using it for muscle cramps (FDA, 2022). While the absolute numbers are small, the impact on quality of life can be substantial.

Symptoms

Quinine‑associated tinnitus may present alone or with other otologic or systemic signs. The symptom list below reflects the full clinical picture.

Auditory Symptoms

• Ringing (high‑frequency tone) – most common; described as “a high‑pitched squeal”.
• Buzzing, hissing, or roaring – lower‑frequency sounds that may be continuous or intermittent.
• Phantom pulsatile noise – often synchronized with the heartbeat, indicating possible vascular involvement.
• Sound‑level fluctuation – symptoms can worsen in quiet environments or after exposure to loud noise.
• Hyperacusis – increased sensitivity to normal sounds, sometimes accompanying tinnitus.
• Temporary threshold shift – a measurable, short‑term reduction in hearing acuity that can accompany tinnitus.

Non‑auditory Symptoms (may accompany quinine toxicity)

• Headache or dizziness
• Nausea, vomiting, or abdominal cramps (classic quinine side‑effects)
• Visual disturbances (blurred vision, photopsia)
• Cardiac arrhythmias or palpitations (especially with high doses)
• Skin rash or itching (sign of hypersensitivity)

Symptoms typically appear within hours to days after starting quinine, but delayed onset up to several weeks has been reported, especially with chronic low‑dose use.

Causes and Risk Factors

Quinine exerts its therapeutic effect by interfering with the malaria parasite’s ability to metabolize hemoglobin. Unfortunately, quinine also affects human cells, particularly the hair cells of the inner ear and the stria vascularis, which are essential for converting sound waves into electrical signals.

Pathophysiology

• Direct ototoxicity – quinine can disrupt ion channels (especially potassium channels) in the cochlear hair cells, leading to altered transduction and spontaneous neural firing that the brain interprets as sound.
• Vasoconstriction – quinine may cause microvascular spasm in the cochlear blood supply, reducing oxygen delivery and precipitating temporary ischemia.
• Immune‑mediated reaction – occasional hypersensitivity may cause inflammation of the inner ear (labyrinthitis), compounding tinnitus.

Risk Factors

• High cumulative dose (> 2 g per day for > 7 days)
• Concurrent use of other ototoxic drugs (e.g., aminoglycoside antibiotics, loop diuretics, NSAIDs)
• Pre‑existing hearing loss, Menière’s disease, or otosclerosis
• Renal insufficiency (eGFR < 60 mL/min/1.73 m²) – reduced clearance increases plasma quinine levels
• Hepatic disease (elevated AST/ALT) – impairs metabolism
• Genetic polymorphisms affecting cytochrome P450 3A4/5 activity (study in *Pharmacogenetics & Genomics*, 2021)
• Age > 50 years

Diagnosis

Diagnosing quinine‑associated tinnitus is largely clinical and requires a detailed medication history combined with audiologic testing.

Step‑by‑Step Diagnostic Approach

1. Medication review – confirm quinine exposure (dose, formulation, duration) and assess for other ototoxic agents.
2. Symptom chronology – correlate onset of tinnitus with start of quinine therapy.
3. Physical otoscopic exam – rule out external or middle‑ear pathology (cerumen impaction, otitis media).
4. Pure‑tone audiometry – detects any concurrent hearing loss and helps quantify the degree of threshold shift.
5. Speech‑in‑noise testing – evaluates functional hearing impact, especially if hyperacusis is present.
6. Tympanometry – assesses middle‑ear pressure; usually normal in drug‑induced tinnitus.
7. Otoacoustic emissions (OAEs) – sensitive to early cochlear hair‑cell dysfunction.
8. Laboratory tests (if needed) – serum quinine level (rarely done), renal & hepatic function, electrolytes.

Because quinine can cause other systemic toxicities, physicians may also order a CBC, ECG, and basic metabolic panel to rule out severe adverse reactions.

Treatment Options

Management focuses on stopping or reducing quinine exposure, alleviating tinnitus, and addressing any co‑existing complications.

1. Discontinuation or Dose Adjustment

• Immediate cessation is recommended if tinnitus is moderate‑to‑severe or accompanied by systemic toxicity.
• If quinine is indispensable (e.g., severe malaria), the dose may be lowered to the minimal effective amount, and alternative agents (artemisinins, atovaquone) should be considered.

2. Pharmacologic Therapies for Tinnitus

• Intravenous or oral corticosteroids – may reduce inflammatory component; limited evidence, typically a short 5‑day taper.
• Melatonin (3–6 mg nightly) – shown in a meta‑analysis (Cochrane, 2022) to improve sleep and reduce perceived tinnitus loudness.
• Antidepressants (tricyclics or serotonin‑norepinephrine reuptake inhibitors) – useful when tinnitus leads to anxiety or depression.
• Ginkgo biloba extract – modest benefit in some trials, though data are mixed; generally safe.

3. Sound‑Therapy & Rehabilitation

• White‑noise generators or hearing aids with built‑in masking – help the brain habituate to the phantom sound.
• Cognitive‑behavioral therapy (CBT) – strong evidence for reducing distress and improving quality of life (American Academy of Otolaryngology‑Head & Neck Surgery, 2020).
• Tinnitus Retraining Therapy (TRT) – combines sound therapy with counseling; success rates of 60‑70 % in chronic cases.

4. Lifestyle & Supportive Measures

• Avoid loud environments; use ear protection (earplugs, noise‑cancelling headphones) when exposure is unavoidable.
• Limit caffeine, nicotine, and alcohol, all of which can exacerbate tinnitus perception.
• Maintain good sleep hygiene – inadequate sleep amplifies tinnitus distress.
• Stay hydrated; dehydration can worsen quinine‑induced vasoconstriction.

Living with Quinine‑Associated Tinnitus

Even after quinine is stopped, some individuals experience persistent tinnitus. Below are practical strategies to integrate into daily life.

• Establish a “quiet time” routine – allocate 15‑30 minutes each evening for gentle sound‑masking (soft music, nature sounds) to promote habituation.
• Mind‑body techniques – meditation, progressive muscle relaxation, and yoga have been shown to lower tinnitus‑related stress (JAMA Otolaryngology, 2021).
• Regular physical activity – improves cardiovascular health and cochlear blood flow, potentially reducing symptom intensity.
• Track triggers – keep a diary of diet, medication changes, and noise exposure to identify patterns.
• Join a support group – both online (e.g., American Tinnitus Association forums) and in‑person groups provide emotional support and coping tips.

Prevention

Because quinine‑associated tinnitus is drug‑induced, prevention centers on responsible prescribing and patient education.

• Prescribe the lowest effective quinine dose and limit treatment duration (≤ 7 days for malaria prophylaxis; ≤ 2 weeks for leg cramps).
• Screen for pre‑existing hearing loss before initiating therapy, especially in older adults.
• Avoid concomitant ototoxic medications whenever possible.
• Educate patients on early warning signs (ringing, visual changes, palpitations) and advise prompt reporting.
• Monitor renal and hepatic function in patients on prolonged quinine courses.
• Consider alternative agents (e.g., meclizine for cramps, artemisinin derivatives for malaria) in high‑risk individuals.

Complications

If left unchecked, quinine‑associated tinnitus can lead to:

• Persistent chronic tinnitus – lasting > 6 months, which may become refractory to treatment.
• Development of sensorineural hearing loss – especially when combined with other ototoxic exposures.
• Psychological sequelae – anxiety, depression, insomnia, and reduced work productivity (CDC, 2023).
• Social withdrawal due to difficulty concentrating in quiet environments.
• In rare cases, progression to ototoxic shock syndrome with systemic quinine toxicity (hypotension, cardiac arrhythmias).

When to Seek Emergency Care

---

Sources: Mayo Clinic, CDC, NIH National Institute on Deafness and Other Communication Disorders, WHO, Cleveland Clinic, FDA Adverse Event Reporting System (FAERS), Cochrane Review 2022, *Pharmacogenetics & Genomics* 2021, JAMA Otolaryngology 2021.